AbbVie Inc. v. Teva Pharmaceuticals, Inc. et al
| AbbVie Inc. |
| Teva Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. |
| 1:2023cv01268 |
| November 7, 2023 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on January 3, 2024. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 10 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,690,845 B2. (Attachments: #1 Order)(nms) |
Filing 9
SO ORDERED Granting #7 Stipulation and Proposed Order of Dismissal (***Civil Case Terminated). Signed by Judge Richard G. Andrews on 1/2/2024. (nms)
|
|
Filing 8
SO ORDERED Granting #6 Stipulation and Proposed Order of Dismissal (*Teva Pharmaceutical Industries Ltd. terminated). Signed by Judge Richard G. Andrews on 1/2/2024. (nms) (Main Document 8 replaced on 1/2/2024) (nms).
|
| DEFICIENCY NOTICE issued by the Court to Defendants: Pursuant to Fed. R. Civ. P. 7.1 (b)(1), A party must: (1) file the disclosure statement with its first appearance, pleading, petition, motion, response, or other request addressed to the court. Counsel is requested to supplement the docket with an appropriate Rule 7.1 Disclosure Statement. (nms) |
| CORRECTING ENTRY: The pdf for D.I. #8 has been replaced with a corrected version. The NEF for the filing has been regenerated. (nms) |
| Filing 7 STIPULATION of Dismissal by AbbVie Inc.. (Tigan, Jeremy) |
| Filing 6 STIPULATION of Dismissal as to Teva Pharmaceutical Industries Ltd., by AbbVie Inc.. (Tigan, Jeremy) Modified on 12/26/2023 (nms). |
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc.. (mpb) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,690,845 B2. (mpb) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 10/20/2023. Date of Expiration of Patent: 8/27/2040.Thirty Month Stay Deadline: 1/23/2026. (mpb) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) |
| Filing 1 COMPLAINT filed against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4267756.) - filed by AbbVie Inc.. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet)(mpb) |
| No Summons Issued. (mpb) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
